Midlife Vitamin D Linked to Lower Tau Years Later: Framingham Study Suggests a Potential Early‑Prevention Signal

 

A longitudinal Framingham analysis found that higher circulating 25‑hydroxyvitamin D measured in midlife (~age 39) was associated with lower tau protein accumulation on PET scans roughly 16 years later. No consistent association was observed between midlife vitamin D and amyloid PET in this sample. The cohort was dementia‑free at imaging; the study is observational and cannot establish causation.

Study design and participants

• Design: Prospective observational analysis within the Framingham Heart Study.
• Sample: Several hundred participants (reported ~700–800) who had stored midlife blood samples and later underwent amyloid and tau PET imaging; all were dementia‑free at time of imaging.
• Exposure: Single baseline measure of serum 25‑hydroxyvitamin D (vitamin D status) taken in midlife (mean age ≈39).
• Outcomes: Regional and global tau PET burden measured ~16 years after the blood draw; amyloid PET assessed in the same imaging protocol.
• Covariates: Models adjusted for age, sex, season of blood draw, APOE genotype, education, cardiovascular risk factors, and other potential confounders where available.

Main findings

• Tau: Higher midlife vitamin D was associated with lower tau PET burden approximately 16 years later; associations were observed in adjusted models and for relevant brain regions linked to Alzheimer’s disease.
• Amyloid: No significant association between midlife vitamin D levels and amyloid PET burden in the studied sample.
• Dementia‑free sample: Imaging occurred in participants without dementia, highlighting potential relevance for early prevention/primary prevention windows.

Effect size and robustness

• Magnitude: Associations were modest but statistically meaningful after covariate adjustment; exact effect estimates varied by region and model specification.
• Sensitivity analyses: Authors typically report checks for confounding (cardiometabolic factors, APOE) and seasonality of vitamin D measurement; results for tau remained suggestive but subject to limitations.

Biological plausibility

• Vitamin D has neuroprotective properties in vitro and is linked to anti‑inflammatory, neurotrophic, and vascular effects that could plausibly influence tau phosphorylation, aggregation, or clearance.
• Lack of association with amyloid suggests vitamin D’s influence—if causal—might act through pathways more closely tied to tau pathology, neuroinflammation, or neurovascular health.

Limitations

• Observational design: Cannot infer causality; residual confounding or unmeasured factors may explain associations.
• Single baseline measurement: Vitamin D status can vary over time; one measure limits inference about long‑term exposure.
• Sample size and selection: PET imaging subsamples can be selected and may limit generalizability.
• Timing and reverse causation: Although midlife exposure precedes imaging, subclinical processes could influence behavior or vitamin D levels; causality remains uncertain.

Implications and next steps

• Research: Replication in other cohorts, studies using repeated vitamin D measures, Mendelian randomization, and randomized controlled trials targeting midlife vitamin D are needed to test causality.
• Prevention: Results are hypothesis‑generating and support further investigation of midlife modifiable factors for downstream tau pathology; they do not justify clinical recommendations to change vitamin D intake solely to prevent tau accumulation without stronger causal evidence.

Citation

Mulligan MD, McGrath E, et al. (2026). Association of Circulating Vitamin D in Midlife With Tau‑PET Burden in Dementia‑Free Adults. Neurology Open Access. DOI: 10.1212/WN9.0000000000000057.